This page contains health-related information for reference only. It is not medical advice. Read full disclaimer
weight loss
Endoscopic Sleeve Gastroplasty
In medicine, endoscopic sleeve gastroplasty (ESG) is a minimally-invasive, non-surgical (incisionless), endoscopic weight loss procedure that is part of the field of endoscopic bariatric therapies. To perform ESG, a physician sutures a patient's stomach into a narrower, smaller tube-like configuration.
Quick Facts
- Price range
- Varies by clinic
- Recovery
- Varies
- Sessions
- Varies
- Category
- weight loss
- Anaesthesia
- Varies
- Min. stay abroad
- Varies
- Price Range (International)
- Varies by clinic
- Average Recovery
- Varies
- Typical Sessions
- Varies
- Category
- weight loss
Overview
Endoscopic sleeve gastroplasty (ESG) is a minimally invasive, non-surgical and incisionless endoscopic weight-loss procedure, and one of the endoscopic bariatric therapies. Rather than removing part of the stomach through incisions, a physician passes an endoscope through the mouth and places sutures that draw the stomach into a narrower, smaller, tube-like configuration. The result is a more restricted stomach that leads patients to feel fuller sooner and eat fewer calories, which facilitates weight loss. Endoscopic bariatric therapies are judged mainly on total body weight loss and excess weight loss. In 2015 a joint expert panel from the American Society for Gastrointestinal Endoscopy and the American Society for Metabolic and Bariatric Surgery recommended that any new endoscopic weight-loss therapy should achieve excess weight loss above 25% with a serious adverse-event rate below 5%, and multiple studies indicate that ESG meets these thresholds. The MERIT study, the first and only randomised controlled trial of ESG for obesity, enrolled 209 adults with class I and II obesity (body mass index 30 to 40) across nine centres in the United States. Participants in the ESG arm lost 13.6% of body weight and 49.2% of excess body weight at one year, compared with 0.8% total body weight loss in the control arm, which received lifestyle modification only.
Key Considerations
Common Risks
Credentials a clinic should hold
Specialty-board certifications and facility-level accreditations relevant to this procedure. Verify on the issuer's public register before booking — most issuers publish a searchable directory.
IFSO Centre of Excellence
Issuer International Federation for the Surgery of Obesity
Facility + surgical-team accreditation for bariatric surgery; requires minimum case volumes, multidisciplinary follow-up, and outcomes reporting.
Verify on the issuer's register →
Current clinical trials
Ongoing research studies registered on ClinicalTrials.gov whose intervention involves endoscopic sleeve gastroplasty. This is a neutral pointer to public research — not an endorsement, not a recruitment drive, and not medical advice. Trial status changes often; confirm eligibility and current status with the study team via each record.
- Not yet recruitingInterventional· Started 2027-02Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)NCT07639684· Boston Scientific Corporation· Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
- Not yet recruitingInterventional· Started 2026-09Endoscopic Sleeve Gastroplasty Technique Comparison for Weight LossNCT06299644· Brigham and Women's Hospital· Obesity, Obesity, Morbid, Metabolic Disease
- Not yet recruitingInterventional· Started 2026-05-04Hormonal and Microbiota Modulation After Endoscopic Sleeve GastroplastyNCT07576777· Assistance Publique - Hôpitaux de Paris· Obesity (Disorder), Metabolic Disorders
- RecruitingObservational· Started 2026-03-31Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT LossNCT06894498· Boston Scientific Corporation· Obesity and Obesity-related Medical Conditions, Weight Loss
- Not yet recruitingObservational· Started 2026-03Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)NCT07449520· IHU Strasbourg· Obesity
- RecruitingInterventional· Started 2025-11-14Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese PatientsNCT07090005· Nitinotes Surgical Ltd.· Obesity, Overweight
Showing 6 recent ongoing studies. Source: ClinicalTrials.gov — all matching trials (U.S. National Library of Medicine, public domain). Retrieved 2026-08-02.
Recovery Timeline
Average recovery for Endoscopic Sleeve Gastroplasty is 0 days. Individual recovery varies — always follow your surgeon’s specific guidance.
- 01Day 0–1
Immediate
First 24–48 hours post-procedure. Monitoring, anaesthesia recovery, initial pain management. Most clinics expect you to remain on-site or nearby.
- 02Day 2–2
Early recovery
Wound care, swelling or bruising peaks, restricted activity. Typical window for follow-up visits and drain removal if applicable. Travel is usually not advised.
- 03Day 3–3
Intermediate recovery
Gradual return to non-strenuous daily activity. Many international patients fly home during this window. Surgeon may require medical clearance for long-haul travel.
- 04Day 4–0
Full recovery
Return to full activity, exercise, and work. Final results may still be settling. Final follow-up with local doctor recommended.
Questions to Ask Your Clinic
Browse all destinations offering Endoscopic Sleeve Gastroplasty →Detailed cost breakdown →
Frequently Asked Questions
What is endoscopic sleeve gastroplasty?
It is a minimally invasive, non-surgical and incisionless endoscopic weight-loss procedure that is part of the field of endoscopic bariatric therapies. A physician sutures the stomach into a narrower, smaller, tube-like configuration.
Does ESG involve incisions or removing part of the stomach?
No. ESG is non-surgical and incisionless. The stomach is reshaped from the inside using sutures placed through an endoscope, rather than through external incisions.
How does ESG cause weight loss?
By suturing the stomach into a narrower, more restricted shape, the procedure forces patients to feel fuller sooner and eat fewer calories, which facilitates weight loss.
Who is ESG studied in?
The MERIT randomised controlled trial enrolled 209 adults with class I and II obesity, defined as a body mass index between 30 and 40, across nine centres in the United States.
How much weight loss does it produce?
In the MERIT study, participants in the ESG arm lost 13.6% of body weight and 49.2% of excess body weight at one year, compared with 0.8% total body weight loss in the control arm, which received lifestyle modification only.
What safety and effectiveness threshold applies to endoscopic weight-loss therapies?
In 2015 a joint expert panel from the American Society for Gastrointestinal Endoscopy and the American Society for Metabolic and Bariatric Surgery recommended that any new endoscopic weight-loss therapy achieve excess weight loss above 25% with a serious adverse-event rate below 5%. Multiple studies indicate that ESG satisfies these criteria.
Conditions treated
Clinical conditions for which endoscopic sleeve gastroplasty is a treatment-ladder option.
Related Procedures
Other weight loss procedures in our registry